Images List Premium Download Classic

Neoplasm

Neoplasm-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Compounds for the modulation of myc activity
Syros Pharmaceuticals, Inc.
June 14, 2018 - N°20180162851

The present invention provides novel compounds of formula (i) and formula (ii) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases, e.g., cancers (e.g., breast cancer, prostate cancer, lymphoma, lung cancer, pancreatic cancer, ovarian cancer, neuroblastoma, ...
Fused bicyclic pyrimidine derivatives and uses thereof
Dana-farber Cancer Institute, Inc.
June 07, 2018 - N°20180153894

The present invention provides novel compounds of formula (i), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., lung cancer, breast cancer, leukemia, lymphoma, melanoma, multiple myeloma, ewing's sarcoma, ...
Therapeutic targeting of myelopoliferative neoplasmas by dusp1 inhibition
Children's Hospital Medical Center
June 07, 2018 - N°20180153877

Methods and compositions disclosed herein generally relate to methods, compounds, and compositions for treating myeloproliferative neoplasms (mpns) or a symptom thereof, comprising administering, to a subject in need thereof, a therapeutically effective amount of a dusp1 inhibiting compound, or of a pharmaceutically acceptable salt, ester, solvate, pharmaceutically usable derivative, or prodrug thereof. Embodiments of the invention also relate to use ...
Neoplasm Patent Pack
Download + patent application PDFs
Neoplasm Patent Applications
Download + Neoplasm-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Neoplasm-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Atomic therapeutic indicator
Atomic Oncology Pty Ltd
May 24, 2018 - N°20180143197

The present invention relates to the generation of an atomic therapeutic indicator (ati) for a test sample by the quantification of manganese; in voxels of a 3d region of the sample, wherein the 3d region is topographically defined by co-ordinates x′×y′×z. The ati is used to assess the radio-responsiveness i.e.
Use of immune checkpoint inhibitors in central nervous systems neoplasms
Bristol-myers Squibb Company
May 17, 2018 - N°20180133313

This disclosure provides a method for treating glioma in a subject comprising administering to the subject an anti-programmed death-1 (pd-1) antibody. In some embodiments, this invention relates to methods for treating glioma in a subject comprising administering to the subject a combination of an anti-cancer agent which is an anti-programmed death-1 (pd-1) anti-body and another anti-cancer agent such as an ...
Method of treating neoplasias
Paranta Biosciences Limited
May 10, 2018 - N°20180125936

The present invention relates generally to a method of treating a neoplastic condition. More particularly, the present invention is directed to a method of selectively sensitising neoplastic cells prior to chemotherapy.
Neoplasm Patent Pack
Download + patent application PDFs
Neoplasm Patent Applications
Download + Neoplasm-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Neoplasm-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Mirna compositions for the treatment of mature b-cell neoplasms
FundaciÓn Centro Nacional De Investigaciones Cardiovasculares Carlos Iii (cnic)
May 03, 2018 - N°20180117076

Provided herein are compositions comprising mir-28, including compositions comprising mirna-28 expression vectors, as well as compositions comprising compounds that mimic the mirna activity of mir-28. In certain embodiments, the compositions comprise oligomeric compounds comprising oligonucleotides having nucleobase sequence identity to mir-28.
Detecting neoplasm
Mayo Foundation For Medical Education And Research
April 19, 2018 - N°20180105886

This document relates to methods and materials for detecting premalignant and malignant neoplasms. For example, methods and materials for determining whether or not a stool sample from a mammal contains nucleic acid markers or polypeptide markers of a neoplasm are provided..
Inhibitors of phosphoglycerate dehydrogenase (phgdh) and uses thereof
Dana-farber Cancer Institute, Inc.
April 19, 2018 - N°20180105508

The present invention provides compounds pounds of formula (ii), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, pro-drugs, and compositions thereof. Also provided are methods and kits involving the compounds of formula (i), (ii) or (iii) for treating diseases associated with the over-expression of phosphoglycerate dehydrogenase (phgdh) in a subject, such as proliferative diseases (e....
Salts and polymorphs of a tetracycline compound
Paratek Pharmaceuticals, Inc.
April 19, 2018 - N°20180104262

Crystalline forms, including salts and polymorphs, of a compound useful in the treatment of tetracycline compound-responsive states are provided herein. The crystalline compounds are useful for the treatment or prevention of conditions and disorders such as bacterial infections and neoplasms, as well as other known applications for tetracycline compounds in general..
Method of diagnosing neoplasms
Commonwealth Scientific And Industrial Research Organisation
April 12, 2018 - N°20180100200

The present invention relates generally to nucleic acid molecules, the rna and protein expression profiles of which are indicative of the onset, predisposition to the onset and/or progression of a neoplasm. More particularly, the present invention is directed to nucleic acid molecules, the expression profiles of which are indicative of the onset and/or progression of a large intestine ...
Compositions and methods for prognosis and treatment of neoplasm
Novazoi Theranostics, Inc.
April 05, 2018 - N°20180095070

A protocol for assessing the prognosis for a patient diagnosed with a neoplasm or suspected of having a neoplasm is provided herein. The protocol involves the steps of determining a mitotic cells to proliferating cells ratio (m:p ratio) in a neoplastic tissue sample obtained from the patient and producing a prognosis for the neoplasm based on the m:p ...
Anti-cd303 monoclonal antibodies
Laboratoire Francais Du Fractionnement Et Des Biotechnologies
March 29, 2018 - N°20180086834

The invention relates to chimeric or humanised anti-cd303 antibodies to nucleic acids coding for the heavy and light chains of these antibodies, expression vectors, host cells, transgenic non-human animals or transgenic plants expressing said antibodies, as well as to the uses thereof in the treatment or prevention of blastic plasmacytoid dendritic cell neoplasms (bpdcn) or inflammatory diseases, in particular autoimmune ...
Neoplasm Patent Pack
Download + patent application PDFs
Neoplasm Patent Applications
Download + Neoplasm-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Neoplasm-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
March 29, 2018 - N°20180085371

For simultaneous, concurrent, separate or sequential use, especially for use in the treatment of proliferative diseases. The invention also relates to pharmaceutical compositions comprising such a combination and to a method of treating proliferative diseases, in a mammal, particularly a human, with such a combination.
Combined composition for preventing or treating cancer comprising a benzophenone thiazole derivatives as a vda ...
National Cancer Center
March 29, 2018 - N°20180085363

The present invention relates to a pharmaceutical combined composition for preventing or treating cancer comprising a compound of formula 1 or a pharmaceutically acceptable salt thereof and topoisomerase inhibitor as active ingredients. The pharmaceutical combined composition of the present invention specifically inhibits cell proliferation and induces apoptosis as to various cancers such as colorectal cancer and ovarian cancer that a vascular ...
Monitoring health and disease status using clonotype profiles
Adaptive Biotechnologies Corp.
March 22, 2018 - N°20180080090

There is a need for improved methods for determining the diagnosis and prognosis of patients with conditions, including autoimmune disease and cancer, especially lymphoid neoplasms, such as lymphomas and leukemias. Provided herein are methods for using dna sequencing to identify personalized, or patient-specific biomarkers in patients with lymphoid neoplasms, autoimmune disease and other conditions.
Enrichment of nucleic acids by complimentary capture
The Johns Hopkins University
March 22, 2018 - N°20180080062

Assays can be used to detect mutations found in neoplasms of the pancreas, as well as for other neoplasms and other uses. Nucleic acids can be captured from body fluids such as cyst fluids.
Combination therapy comprising an inhibitor of jak, cdk, and pim
Novartis Ag
March 15, 2018 - N°20180071296

The present invention relates to a pharmaceutical combination which comprises (a) a jak inhibitor compound, (b) a cdk inhibitor, and (c) a pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use ...
1-amino-triazolo(1,5-a)pyridine-substituted urea derivative and uses thereof
Kala Pharmaceuticals, Inc.
March 01, 2018 - N°20180057489

Provided herein is a compound, 1-(4-(3-amino-[1,2,3]triazolo[1,5-a]pyridin-4-yl)phenyl)-3-(3-chlorophenyl)urea, pharmaceutical compositions thereof and crystal forms thereof. Also provided are particles (e.g., nanoparticles) comprising the compound, and pharmaceutical compositions thereof that are mucus penetrating.
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to ...
Cellectis
February 22, 2018 - N°20180051089

The present invention relates to a tcr ko—or tcr ko and dck ko—engineered immune cells expressing a chimeric antigen receptors (car) specific for cd123 that is a recombinant chimeric protein able to redirect immune cell specificity and reactivity toward cd123-expressing cells, and more particularly in which extracellular ligand binding is a scfv derived from a ...
Urea derivatives and uses thereof
Kala Pharmaceuticals, Inc.
February 08, 2018 - N°20180037573

The present invention provides novel compounds of any one of formulae (i)-(iii), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of formula (i)-(iii) and pharmaceutical compositions thereof that are mucus penetrating.
Loading